Menu

FAQ Directory

Here are some of the most frequently asked questions about NCQA’s various programs. If you don’t see what you are looking for in one of the entries below, you can  ask a question through My NCQA.

Filter Results
  • Save

    Save your favorite pages and receive notifications whenever they’re updated.

    You will be prompted to log in to your NCQA account.

    Save your favorite pages and receive notifications whenever they’re updated.

    You will be prompted to log in to your NCQA account.

  • Email

    Share this page with a friend or colleague by Email.

    We do not share your information with third parties.

    Share this page with a friend or colleague by Email.

    We do not share your information with third parties.

  • Print

    Print this page.

    Print this page.

You are viewing a single FAQ from your previous search. Clear Search

expand all

11.14.2014 Osteoporosis Management in Women Who Had a Fracture CMS required the use of temporary HCPCS code Q2051 (Injection, Zoledronic acid, 1 mg) from July 1–December 31, 2013. This code is not included in the Osteoporosis Medications Value Set. May organizations map this code and use it for HEDIS 2015 reporting?

Yes. Organizations may map Q2051 to J3489 (which is included in the Osteoporosis Medications Value Set and is for the same medication and dose) for HEDIS 2015 reporting. Auditors review mapped codes as part of the HEDIS Compliance Audit.

ALL 2015